Enlitic (ASX:ENL) locks in A$15m raise and finally clears the convertible note overhang

Pro forma cash of A$18m and a debt-free balance sheet reset the story

Enlitic (ASX:ENL) has done the housekeeping investors have been waiting on for months. The medical imaging AI company today confirmed binding commitments for a A$15 million conditional placement at A$0.004 per new CDI, alongside a plan to convert its A$8 million convertible note pile into equity and follow up with a 10:1 share consolidation.

The placement is priced at a 20% discount to the last close of A$0.005, which is not a small haircut. But at a share price that low, the maths of a normal raise gets ugly quickly, and management appears to have accepted that in exchange for finality.

Post-completion, Enlitic expects to sit on roughly A$18 million in pro forma cash with no debt, plus an SPP targeting a further A$1 million. CEO Michael Sistenich is participating personally alongside his associated entities for A$827,500, which is worth noting given how often ASX small-cap capital raises happen without any insider skin in the game.

The company says this raise takes it all the way to cashflow break-even. That is the claim the rest of the article needs to examine.

Why converting the notes matters more than the fresh cash

The A$15 million placement is the headline number, but the convertible note conversion is arguably the more important piece. Enlitic raised A$8 million through secured convertible notes back in December 2025, and those notes have sat on the balance sheet as a structural overhang ever since.

Under the new deal, noteholders convert the full A$10 million total amount (face plus all accrued and capitalised interest) into CDIs at the same A$0.004 placement price. Interest entitlements are irrevocably waived. That is a clean extinguishment of secured debt in exchange for equity, and it removes a repayment cliff the market has been quietly pricing in.

The trade-off is dilution, and it is substantial. Enlitic goes from 833 million shares on issue to roughly 7.08 billion before the 10:1 consolidation. Existing holders who do not participate in the SPP will feel that.

The Ensight commercialisation push is what the cash is actually for

Strip out the corporate and restructure costs, and roughly A$8.8 million of the A$15 million is going into what most investors would call growth spend. R&D takes A$3.6 million, sales and marketing gets A$2.8 million, and strategic development pulls another A$1.2 million.

The commercial story sits with Ensight, Enlitic’s SaaS platform for standardising and analysing medical imaging data across radiology workflows. Management is pointing at enterprise healthcare rollouts and a growing OEM partner channel as the two paths to scale.

The skeptical read is that Enlitic has been talking about this pipeline for a while, and the cashflow break-even claim ultimately depends on that pipeline converting. Investors should read the Key Risks section of the Investor Presentation carefully before taking the break-even guidance at face value.

The Investors Takeaway for Enlitic

This is a genuine reset. Enlitic emerges debt-free, with over 12 months of runway on management’s numbers and a share structure that finally makes sense after the 10:1 consolidation. Insider participation adds credibility to the pitch.

The bull case rests entirely on execution from here. If Ensight starts producing recurring SaaS revenue at the pace management implies, the A$18 million lasts long enough to get there. If the enterprise sales cycle drags, this raise buys time rather than solves the problem, and the market will start pricing the next one well before it arrives. Investors can find more coverage of ASX-listed healthcare AI names at stocksdownunder.